SWOG clinical trial number
SWOG-8704
Neoadjuvant Methotrexate, Cisplatin and Vinblastine (MCV) Followed by Concomitant Cisplatin/Radiotherapy for Unresectable Localized Bladder Cancer Patients
Closed
Phase
Accrual
90%
Published
Abbreviated Title
Neoadjuvant Methotrexate, Cisplatin and Vinblastine (MCV) Followed by Concomitant Cisplatin/Radiotherapy for Unresectable Localized Bladder Cancer Patients
Activated
09/01/1987
Closed
08/15/1991
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
1996
Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: A Phase I/II Southwestern Oncology Group study.
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase